Lymphatic metastasis after kidney cancer surgery can only be treated by medication and radiotherapy in general. It is more difficult to cure patients with lymphatic metastasis and the 5-year survival rate is 5-30%. If the tumor does not recur within 5 years, there is a higher probability that the patient has regained health and does not affect the natural life span. Lymphatic metastasis after kidney cancer surgery is difficult to be cured, which usually represents that kidney cancer has developed to advanced stage, with 5-year survival rate of 5%~30%, and it can only be treated by medication and radiotherapy to relieve pain and control the condition. Drug therapy is mainly targeted therapy, and the targeted drugs for advanced kidney cancer include sorafenib, sunitinib, pazotinib, teicoplanin, everolimus and bevacizumab combined with IFN-alpha. Radiotherapy is mainly to give palliative radiotherapy to patients with lymphatic metastasis, to achieve the purpose of pain relief and improve the quality of survival. Patients should pay attention to maintaining a good state of mind, which is very helpful to the treatment of the disease. And appropriate physical exercise, regular follow-up, in order to timely understand the changes in the condition and adjust the treatment program.